| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms | Details |
| Rogaratinib | BAY-1163877 | Phase 2 Clinical | Bayer AG | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms | Details |
| Fisogatinib | BLU-554; CS-3008 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Hepatocellular | Details |
| BB-102 | BB-102; BB102 | Phase 2 Clinical | Broadenbio Co Ltd | Carcinoma, Hepatocellular; Solid tumours | Details |
| Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Irpagratinib | ABSK-011 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours | Details |
| BPI-43487 | BPI-43487 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours | Details |
| HS-236 | HS-236 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
| HS-10340 | HS-10340 | Phase 1 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | Details |
| ICP-105 | ICP-105 | Phase 1 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours | Details |
| ZSP-1241 | ZSP-1241 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Biliary Tract Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Stomach Neoplasms | Details |
| H3B-6527 | H3B-6527 | Phase 1 Clinical | H3 Biomedicine Inc | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| FGFR4-CAR T Cells Therapy(National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Rhabdomyosarcoma | Details | |
| TYRA-430 | TYRA-430 | Phase 1 Clinical | Tyra Biosciences Inc | Carcinoma, Hepatocellular; Neoplasms; Solid tumours | Details |
| SYHX-2005 | SYHX-2005; SYHX2005 | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Solid tumours | Details |
| JAB-6343 | Phase 1 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details | |
| SY-4798 | SY-4798 | Phase 1 Clinical | Shouyao Holding (Beijing) Co Ltd | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours | Details |
| ABSK-012 | ABSK-012; ABSK012 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib Mesilate | E-7080; MK-7902; ER-203492-00 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Futibatinib | TAS-120 | Approved | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms | Details |
| Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa, 博珂 | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Adenocarcinoma; Bile Duct Neoplasms; Bone metastases; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Ependymoma; Esophageal Neoplasms; Glioma; Hepatic Insufficiency; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile | Details |